In contrast, in renal carcinoma, pancreatic adenocarcinoma, and glioblastoma, GBP2 overexpression promotes malignancy, often by facilitating immune evasion or Stat3-driven invasion, leading to a poorer prognosis [25,26,31,43]. The gene discussed is GBP2; the disease is renal carcinoma.